Partner Therapeutics Receives Orphan Drug Designation for Leukine (sargramostim) – Odessa American

LEXINGTON, Mass., Sept. 19, 2019 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Leukine (sargramostim), a yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhuGM-CSF), for the potential treatment of Stage IIb-IV melanoma.

Melanoma is the most aggressive form of skin cancer and rates of melanoma have been rising for the past 30 years. The American Cancer Society estimates 96,480 new melanoma cases will be diagnosed in the US and 7,230 people will die from the disease in 2019. The FDA grants orphan drug designation to promote the development of promising treatments for conditions that affect 200,000 or fewer U.S. patients annually. If a product holding Orphan Drug Designation receives the first FDA approval for the disease in which it has such designation the company qualifies for, among other things, seven years of market exclusivity following marketing approval.

The Eastern Cooperative Oncology Group (ECOG) previously reported results of Study 1608, a Phase II study in which patients with advanced stage melanoma received a combination of sargramostim and ipilimumab or ipilimumab alone1. Among 245 patients, the addition of sargramostim led to longer survival (median 17.5 vs 12.7 months). The most common Grade 3-5 toxicities in patients treated with sargramostim and ipilimumab were diarrhea (12.7%) and rash (9.3%) and occurred at similar rate in patients receiving ipilimumab alone. Overall, severe toxicities occurred less frequently in patients treated with sargramostim plus ipilimumab vs ipilimumab alone (44.9% vs 58.3%, Grade 3-5); the most notable reductions were in gastrointestinal and pulmonary toxicities. The results of this study led to initiation of a larger Phase 2/3 study (ECOG 6141) evaluating sargramostim in combination with ipilimumab and nivolumab as initial treatment of advanced or metastatic melanoma. This ongoing study is being conducted by ECOG with support from the National Cancer Institute.2

"Leukine's role as an immunomodulator was not the initial focus when it was first discovered decades ago. As we learn more about the immunologic effects of GM-CSF on antitumor immunity, we believe there is potential to develop Leukine to help more patients benefit from treatment with checkpoint inhibitors in melanoma and other difficult to treat cancers," said Bob Mulroy, PTx's CEO. "This orphan designation is an important step in the development of Leukine. We are pleased FDA has programs such as Orphan Drug Designation to support research in rare diseases."

Leukine was initially approved in the United States in 1991 and has five hematologic oncologic indications. Leukine is currently not approved for the treatment of melanoma. The approval of an orphan drug designation request does not alter the standard regulatory requirements and processes for obtaining marketing approval of an investigational drug. Sponsors must establish safety and efficacy of a compound in the treatment of a disease through adequate and well-controlled studies.

Please see full Prescribing Information for LEUKINE at http://www.leukine.com

About Leukine (sargramostim)

Leukine is a yeast-derived recombinant humanized granulocyte-macrophage colony stimulating factor (rhuGM-CSF) and the only FDA approved GM-CSF. GM-CSF is an important leukocyte growth factor known to play a key role in hematopoiesis, effecting the growth and maturation of multiple cell lineages as well as the functional activities of these cells in antigen presentation and cell mediated immunity3.

Important Safety Information for LEUKINE (sargramostim)

Contraindications

LEUKINE is contraindicated in patients with known hypersensitivity to human granulocyte-macrophage colony stimulating factor such as sargramostim (GM-CSF), yeast-derived products, or any component of LEUKINE.

Warnings and Precautions

Serious hypersensitivity reactions, including anaphylactic reactions, have been reported with LEUKINE. If any serious allergic or anaphylactic reaction occurs, immediately discontinue LEUKINE therapy and institute medical management. Permanently discontinue LEUKINE in patients with serious allergic reactions.LEUKINE can cause infusion-related reactions, including respiratory distress, hypoxia, flushing, hypotension, syncope and/or tachycardia. Observe closely during infusion, particularly in patients with preexisting lung disease, as dose adjustment or discontinuation may be required.Do not administer LEUKINE simultaneously with or within 24 hours preceding cytotoxic chemotherapy or radiotherapy or within 24 hours following chemotherapy.Edema, capillary leak syndrome, pleural and/or pericardial effusion have been reported in patients after LEUKINE administration. LEUKINE should be used with caution and monitored in patients with preexisting fluid retention, pulmonary infiltrates, or congestive heart failure.Supraventricular arrhythmia has been reported in uncontrolled studies during LEUKINE administration, particularly in patients with a previous history of cardiac arrhythmia. Use LEUKINE with caution in patients with preexisting cardiac disease.If ANC > 20,000 cells/mm3 or if WBC counts > 50,000/mm3, LEUKINE administration should be interrupted or the dose reduced by half. Twice weekly monitoring of CBC with differential should be performed.LEUKINE therapy should be discontinued if disease progression is detected during treatment.Treatment with LEUKINE may induce neutralizing anti-drug antibodies. Use LEUKINE for the shortest duration required.Liquid solutions containing benzyl alcohol (including LEUKINE Injection) or LEUKINE for Injection reconstituted with Bacteriostatic Water for Injection, USP (0.9% benzyl alcohol) should not be administered to neonates and low birth weight infants.Concomitant use of drugs that can potentiate the myeloproliferative effects of LEUKINE should be avoided.

Adverse Reactions

Adverse events occurring in >10% of patients receiving LEUKINE in controlled clinical trials and reported in a higher frequency than placebo are:

In Autologous bone marrow transplantation (BMT) patientsasthenia, malaise, diarrhea, rash, peripheral edema, urinary tract disorderIn Allogeneic BMT patientsabdominal pain, chills, chest pain, diarrhea, nausea, vomiting, hematemesis, dysphagia, GI hemorrhage, pruritus, bone pain, arthralgia, eye hemorrhage, hypertension, tachycardia, bilirubinemia, hyperglycemia, increase creatinine, hypomagnesemia, edema, pharyngitis, epistaxis, dyspnea, insomnia, anxiety, high glucose, low albuminIn AML patientsfever, weight loss, nausea, vomiting, anorexia, skin reactions, metabolic laboratory abnormalities, edema

Please see full Prescribing Information for LEUKINE at http://www.leukine.com

Indications and Usage

LEUKINE (sargramostim) is a leukocyte growth factor indicated for the following uses:

LEUKINE is indicated to shorten time to neutrophil recovery and to reduce the incidence of severe, life-threatening, or fatal infections following induction chemotherapy in adult patients 55 years and older with acute myeloid leukemia (AML).LEUKINE is indicated in adult patients with cancer undergoing autologous hematopoietic stem cell transplantation for the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis.LEUKINE is indicated for the acceleration of myeloid reconstitution following autologous peripheral blood progenitor cell (PBPC) or bone marrow transplantation in adult and pediatric patients 2 years of age and older with non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) and Hodgkin's lymphoma (HL).LEUKINE is indicated for the acceleration of myeloid reconstitution in adult and pediatric patients 2 years of age and older undergoing allogeneic bone marrow transplantation from HLA-matched related donors.LEUKINE is indicated for the treatment of adult and pediatric patients 2 years and older who have undergone allogeneic or autologous bone marrow transplantation in whom neutrophil recovery is delayed or failed.LEUKINE is indicated to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]).

About Partner Therapeutics, Inc.:

PTx is an integrated commercial-stage biotech company focused on the development and commercialization of therapeutics that improve health outcomes in the treatment of cancer. PTx's development focus spans the entire range of cancer therapy from primary treatments to supportive care. The company believes in delivering great products with the purpose of creating the best possible outcomes for patients and their families.

References: 1. Hodi FS, et al. Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma A Randomized Clinical Trial. JAMA. 2014;312(17):1744-1753

2. National Cancer Institute. Nivolumab and ipilimumab with or without sargramostim in treating patients with stage III-IV melanoma that cannot be removed by surgery. Available at: https://clinicaltrials.gov/ct2/show/NCT02339571. NLM identifier: NCT02339571. Accessed August 26, 2019

3. Armitage JO. Blood. 1998;92(12):4491-4508

View original content to download multimedia: http://www.prnewswire.com/news-releases/partner-therapeutics-receives-orphan-drug-designation-for-leukine-sargramostim-300921156.html

SOURCE Partner Therapeutics, Inc.

Read more:
Partner Therapeutics Receives Orphan Drug Designation for Leukine (sargramostim) - Odessa American

Stem Cells Market Predicted to Surpass US$167.33 Bn By 2025 – TheSlapClap

In theglobal stem cells marketa sizeable proportion of companies are trying to garner investments from organizations based overseas. This is one of the strategies leveraged by them to grow their market share. Further, they are also forging partnerships with pharmaceutical organizations to up revenues.

In addition, companies in the global stem cells market are pouring money into expansion through multidisciplinary and multi-sector collaboration for large scale production of high quality pluripotent and differentiated cells. The market, at present, is characterized by a diverse product portfolio, which is expected to up competition, and eventually growth in the market.

Some of the key players operating in the global stem cells market are STEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.

Request a Sample of Stem Cells Market Report

As per a report by Transparency Market Research, the global market for stem cells is expected to register a healthy CAGR of 13.8% during the period from 2017 to 2025 to become worth US$270.5 bn by 2025.

Depending upon the type of products, the global stem cell market can be divided into adult stem cells, human embryonic stem cells, induced pluripotent stem cells, etc. Of them, the segment of adult stem cells accounts for a leading share in the market. This is because of their ability to generate trillions of specialized cells which may lower the risks of rejection and repair tissue damage.

This review is based on the findings of a TMR report, titled, Stem Cells Market (Product Adult Stem Cell, Human Embryonic Stem Cell, and Induced Pluripotent Stem; Sources Autologous and Allogeneic; Application Regenerative Medicine and Drug Discovery and Development; End Users Therapeutic Companies, Cell and Tissues Banks, Tools and Reagent Companies, and Service Companies) Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 20172025.

Read the original post:
Stem Cells Market Predicted to Surpass US$167.33 Bn By 2025 - TheSlapClap

Story of life: Seven wonders of biological research – The Irish Times

Everyone has heard of the seven wonders of the ancient world. Today I present my verdict on seven wonder discoveries in biological research, listed in rough chronological order.

Wonder 1: Cell TheoryCell theory, formulated in 1839, made three assertions: (a) All organisms are composed of basic units called cells; (b) The cell is the basic unit of structure and organisation in all living organisms; (c) New cells arise only from pre-existing cells.

Cell theory rationalised basic biology and contradicted the common notion that life can arise spontaneously from non-living matter.

Wonder 2: The Theory of Evolution Through Natural Selection.This is the most significant-ever insight into biology and was jointly proposed in 1858 by Charles Darwin (1809-1882) and Alfred Russell Wallace (1823-1913). It was already known that life on earth changes over long time periods. The theory of evolution explained the mechanism underpinning these changes natural selection. This theory draws all biology together into one unified framework. In its absence, biology would be reduced to a vast catalogue of unrelated observations.

Wonder 3: The Chemistry of LifeLife, unlike mechanical machines, works close to room temperature and without the assistance of significant temperature or pressure gradients. How then do cells grow, divide and create local order in a world that otherwise moves towards increasing disorder? This question was answered by biochemistry the chemistry of life.

A living cell is the end product of co-ordinated reactions between its innumerable chemical constituents metabolism. These reactions must proceed fast enough at room temperature to sustain life, and this is enabled by protein catalysts called enzymes, discovered in the 1800s. Cell metabolism is driven by energy, ultimately supplied by sunlight.

Wonder 4: Antibiotics and VaccinationsAntibiotics, discovered in 1928, are used to kill pathogenic microbes, and vaccination to provide immunity against disease has been in widespread use since 1900. Vaccination has eliminated many deadly diseases, including smallpox and polio.

Average life expectancy in 1900 was 50 years; today that figure is 82 years. Antibiotics and immunisation are one significant cause of this improvement. If we lost antibiotics and vaccinations today, life expectancy would gradually revert to 50-60 years.

Wonder 5: Discovering the Structure of DNAFaithful inheritance of parental characteristics by offspring is essential for biological evolution. The nature of the cells hereditary material was identified as nucleic acid (DNA) in 1944. In 1953, James Watson (born in 1928) and Francis Crick (1916-2004) made the greatest biological discovery of the 20th century when they solved the structure of DNA, a discovery that also indicated how DNA replicates and transmits genetic information from generation to generation.

DNA is a long molecule made of four sub-units A,T,G,C. Genetic information is encoded in the linear sequence (genes) of these subunits, dictating the structure/activity of all cell proteins, including all enzymes, thereby controlling the activities of the cell. Understanding DNA unlocked the secret of the molecular logic of life.

Wonder 6: CloningEvery animal body cell, including cells of the early embryo, contains a full set of the animals genes. Therefore, inducing any body cell into developing as embryonic cells develop should produce a genetic copy of the animal a clone. In 1996 Dolly the sheep was cloned in this manner.

Cloning offers many huge potential benefits, eg cloning animals, genetically modified to secrete a human hormone, to produce herds secreting large quantities of the hormone for use by patients deficient in the hormone. Cloning could also rebuild endangered animal populations or revive extinct animals.

Wonder 7: Induced Pluripotent Stem CellsThe human body is composed of over 200 tissues/organs skin, liver etc. Each tissue cell is differentiated to do a particular job. But all tissue cells develop from embryonic undifferentiated pluripotent stem cells.

In 2006 Shinya Yamanaka discovered how to transform differentiated body cells into pluripotent stem cells. These induced pluripotent stem cells (IPSC) can be coaxed to develop into specific adult tissues.

IPSCs have huge potential in many areas, eg regenerative medicine. New organs could be grown from patients own IPSCs to replace failing organs and without fear of immune rejection.

IPSCs are extremely useful for many research purposes, eg testing new drugs, and can substitute for stem cells extracted from human embryos, thereby avoiding ethical problems.

William Reville is an emeritus professor of biochemistry at UCC

Read the original here:
Story of life: Seven wonders of biological research - The Irish Times

Cell Harvester Market Share, Growth by Top Company, Region, Applications, Drivers, Trends & Forecast to 2025 – Market Forecast

Cell harvester is a device in which cells are regenerate, and that regenerative cells further used in transplantation and repair the affected organs. Biopharmaceuticals industry and related downstream process are mainly dependent on cell harvesting techniques. Cell harvester plays an important role in treating various types of diseases such as cancers, immune-deficiency related diseases, blood-related disorder, etc. In some Burn cases, cell harvesting is also beneficial to the victim in the form of grafting new skin cells. Several Bio-Pharma companies are trying to manufacture regenerating medicine by focusing regenerative myocardial tissue ability by cell grafting method in which adult stem cell injected into the patient. Cell harvester can also be used in eye disease treatment. Some companies are also manufacturing such devices which consist passive flexible drilling unit as well as cell harvesting system that are used in bone marrow transplantation. Cell harvesters market is growing tremendously due to the broad spectrum of cell harvester usage. Biopharmaceutical Company's attractiveness towards regenerative medicine is the reason for the rapid increment of the cell harvester market growth.

Cell Harvester market: Drivers and Restraint

Increasing incidence and prevalence of blood cancer, blood-related disease, increasing organ transplantation procedure rate, improving healthcare expenditure are considered as the driver for the cell harvester market. Multipurpose use of cell harvester also drives the growth of cell harvester market. The complexity of the procedure, less of awareness and lack of reimbursement, this factor may restrain the growth of cell harvester market.

Cell harvester market: Segmentation

The global market for Cell Harvester segmented by product type, modality, end user, and geography:

Based on modality, Automated Manual Auto-trap

Based on application Cell Proliferation Assays Mixed Lymphocyte Culture (MLC) Assays Receptor-binding Assays Single-Stranded Template DNA Harvesting

Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/cell-harvester-market.html

Based on end-user Research Centers Academics Institutes Diagnostic Labs Hospitals

Segmented by geography North America Latin America Europe Asia Pacific The Middle East and Africa

Cell Harvester Market: Overview

Cell harvesting systems market shows promising growth owing to equipment efficacy and accuracy during cells harvest. By application type, Cell Proliferation Assays is anticipated to hold the major share in the cell harvesting systems market owing to less process error, safe and simple procedure and fewer side effects.

By product modality, cell harvester segmented into three categories whereas, automated cell harvester devices are widely used in worldwide.

Based on the end user, cell harvester can be used by several end user such as research centers. Hospital ,Academic Institutes, etc., research center, share large percentage as end user followed by the hospital.

Cell Harvester Market: Region-wise Outlook

By regional, global Cell Harvester market is segmented into five key regions viz. North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. Asia Pacific dominates the global cell harvester market followed by Europe and will continue to dominate the global Cell Harvester market attributed to holding high potential and rising growth in terms of wide acceptance of cell harvester technology. Furthermore, increasing rate of procedures and improving healthcare expenditure also expected to boost the global cell harvester market over the forecasted period. North America is expecting emerging market for the cell harvester market.

Request Brochure of this report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22721&source=atm

Cell Harvester Market: Key Market Participants

Key players of the cell harvesting systems market are PerkinElmer Inc. Tomtec, Bertin Technologies, TERUMO BCT, INC., hynoDent AG, Avita Medical, Argos Technologies, Inc., SP Scienceware, Teleflex Incorporated., Arthrex, Inc., Thomas Scientific, BRAND GMBH

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on: Market segments and sub-segments Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological breakthroughs Value chain and stakeholder analysis

The regional analysis covers: North America (U.S. and Canada) Latin America (Mexico, Brazil, Peru, Chile, and others) Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg) Eastern Europe (Poland and Russia) Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand) Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market Important changes in market dynamics Market segmentation up to the second or third level Historical, current, and projected size of the market from the standpoint of both value and volume Reporting and evaluation of recent industry developments Market shares and strategies of key players Emerging niche segments and regional markets An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request For Discount On This Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=22721&source=atm

See original here:
Cell Harvester Market Share, Growth by Top Company, Region, Applications, Drivers, Trends & Forecast to 2025 - Market Forecast

This Womans Toothache Medication Actually Turned Her Blood Blue – Prevention.com

The New England Journal of Medicine 2019.

When you take medication, you expect that it will work to make you feel better. What you dont expect is that it will turn you blue. Unfortunately, thats what happened to one woman in Rhode Islandand she ended up in a case report.

The 25-year-old woman, who was not publicly identified, went to an emergency room in Providence, Rhode Island, with generalized weakness, fatigue, shortness of breath, according to The New England Journal of Medicine. She was also concerned about the fact that she was, you know, turning blue.

After evaluating her, the womans doctors determined that she was turning blue thanks to a numbing agent she had used. She reported having used large amounts of topical benzocaine the night before for a toothache, the case report authors wrote.

The woman was diagnosed with methemoglobinemia, a blood disorder where an abnormal amount of methemoglobin is produced. Methemoglobin is a form of hemoglobin, the protein in red blood cells that carries and distributes oxygen to the body, according to the U.S. National Library of Medicine. However, it is a dark pigment that causes blood to appear very dark in color, says Jamie Alan, PhD, an assistant professor of pharmacology and toxicology at Michigan State University.

There is normally a small percentage of this compound in the red blood cells, however it is kept very low, she explains. But certain compounds like benzocaine can accelerate the formation of methemoglobin. The result? Hemoglobin cannot successfully release critical oxygen to the tissues, so the body turns blue.

Methemoglobinemia is usually either inherited from your family or caused by exposure to certain chemicals, medicines, or foods, the U.S. National Library of Medicine says. Those can include anesthetics like benzocaine, nitrobenzene (which is used in some drugs, pesticides, and dyes), certain antibiotics like dapsone and chloroquine, and nitrates (which are used as additives to keep meat from spoiling).

Benzocaine and similar compounds used to be in infant and childrens teething gels, but it was taken out of those products because of this exact thing, Alan says.

A bluish tint to the skin is a major symptom of methemoglobinemia, but a person can also have a headache, giddiness, altered mental state, fatigue, shortness of breath, and lack of energy.

Methemoglobinemia is very harmful, Alan says. The problem is that methemoglobinemia reduces the ability of your red blood cells to carry oxygen. This can lead to heart attack, stroke, organ damage, and death, she adds.

A medication called methylene blue is used to treat severe cases of methemoglobinemia and ascorbic acid (aka vitamin C) can also be used to reduce the amount of methemoglobin in a patients blood, the U.S. National Library of Medicine says. Undergoing hyperbaric oxygen therapy, a blood cell transfusion, and exchange transfusions (where a persons blood is removed and replaced) can also be helpful.

People dont usually need treatment for mild cases of methemoglobinemia, thoughthey should just avoid the medication or chemical that caused their condition in the first place. The half life of methemoglobin is 55 minutes, meaning the condition will usually reverse in hours, Alan says. In the meantime, the patient needs supportive care with oxygen.

If you suspect youve developed methemoglobinemia, see a doctor immediately.

Like what you just read? Youll love our magazine! Go here to subscribe. Dont miss a thing by downloading Apple News here and following Prevention. Oh, and were on Instagram too.

More:
This Womans Toothache Medication Actually Turned Her Blood Blue - Prevention.com

SCD: Hypertension Tablet May Prevent Vaso-Occlusive Crisis, Study Says – Sickle Cell Anemia News

A medication used to treat high blood pressure, called valsartan, may help decrease the stickiness of red blood cells and reduce the risk of vaso-occlusive crisis in people with sickle cell disease (SCD), a research study suggests.

The study, Valsartan impedes epinephrine-induced ICAM-4 activation on normal, sickle cell trait and sickle cell disease red blood cells, was published in the journal PLOS One.

SCD is characterized by the production of abnormal hemoglobin proteins, resulting in red blood cells (RBCs) that are stickier and more prone to aggregate together and to blood vessel walls. When such RBC clumps are formed, they can cause painful blockage of blood vessels, a condition that is called vaso-occlusive crisis(VOC).

This blockage process is in part due to abnormally high activation of cell surface proteins, including the intercellular adhesion molecule-4 (or ICAM-4) that mediates RBC clumps binding to blood vessel walls.

Previous studies have suggested that the hormone epinephrine (commonly known as adrenaline) can also contribute to the increased production of ICAM-4 molecules at the surface of RBCs in response to physical stress.

This research led scientists from the University of Connecticut to explore whether using an inhibitor to block the signals of epinephrine could be beneficial in preventing vaso-occlusive episodes. They evaluated the impact of valsartan, an approved oral therapy to reduce blood pressure and treat congestive heart failure, which is sold with the brand name Diovan by Novartis.

The study enrolled five healthy volunteers, three patients with sickle cell trait (SCT, who have both normal and mutated hemoglobin variants), and six patients with diagnosed SCD, who provided blood samples for analysis.

The team used a technique called atomic force microscopy to collect information on the stickiness status of blood cells. This approach can specifically determine the binding force between ICAM-4 at the surface of RBCs to the blood vessel walls.

The researchers found that the binding frequency of ICAM-4 to vessel walls increased in the presence of epinephrine in all three groups. We observed that epinephrine significantly increased the surface percentage of active ICAM-4 receptors, they wrote.

Treatment with valsartan significantly decreased ICAM-4-binding to 10.41% from 17% in RBC samples of healthy volunteers. Similar results were seen in both SCT and SCD samples, with valsartan lowering epinephrine-induced levels of ICAM-4 to 6.87% from 17.11% in SCT blood samples, and to 10.07% from 20.58% in SCD samples.

Supported by these findings, the researchers said that administration of valsartan could mitigate the vaso-occlusive consequences of SCD and may open new avenues for the development of novel therapeutic targets.

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

Continue reading here:
SCD: Hypertension Tablet May Prevent Vaso-Occlusive Crisis, Study Says - Sickle Cell Anemia News

Celsius Therapeutics Signs Multiple Agreements with Academic Institutions to Access Samples for the Identification of Novel Targets in Immune…

Sept. 19, 2019 12:30 UTC

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celsius Therapeutics, a company focused on bringing personalized medicine to patients with cancer, autoimmunity and other complex diseases, today announced the signing of collaboration agreements with the Parker Institute for Cancer Immunotherapy (San Francisco, USA), Institut Gustave Roussy (Paris, France) and the University Health Network (Toronto, Canada). Under these three agreements, Celsius will apply its proprietary single-cell genomics platform to tissue samples from patients receiving immune checkpoint inhibitor therapies for triple negative breast cancer, bladder cancer and kidney cancer, respectively. The goal of these collaborations is the discovery of novel molecular mechanisms and targets for drug discovery.

We are delighted to collaborate with these premier academic groups, given their disease expertise and their commitment to cutting-edge research and improving the lives of cancer patients, said Tariq Kassum, M.D., chief executive officer of Celsius. The heterogeneity of response in immunotherapy studies suggests that a deeper understanding of disease biology and patient subpopulations is needed to fully realize the potential of this approach. These new partnerships highlight our interest in broadly engaging the academic community to better elucidate the cellular ecosystem of cancer, with the ultimate goal of translating new insights into novel precision medicines for patients.

Under these agreements, Celsius will apply its platform approach to generate single-cell data from patient biopsy samples taken pre- and post-treatment with checkpoint inhibitors. In each case, Celsius retains the ability to integrate the clinical information and single-cell genomics data generated from the studies into its growing database. The company plans to utilize its machine learning algorithms and functional genomics capabilities to rapidly identify and prioritize targets for drug discovery.

Our integrated platform allows Celsius to obtain samples from anywhere in the world, process them in a highly industrialized manner and rapidly deploy a suite of machine learning algorithms to identify new drug targets in relevant cell types, said Christoph Lengauer, Ph.D., co-founder and chief scientific officer of Celsius. Across just these three collaborations, we expect to analyze more than 300 longitudinal samples from over 150 patients, a scale that is unprecedented for single-cell genomics. Combined with the associated clinical data that is being gathered from these studies, we are building a massive database that will be leveraged to develop novel precision medicines.

About Celsius Therapeutics

Celsius Therapeutics is charting a new course of target and drug discovery by applying a systematic approach to single-cell sequencing of patient tissue, combining massive datasets, complex algorithms, and machine learning to discover first-in-class precision therapies with a transformative impact on the lives of patients with autoimmune diseases and cancer. Celsius was launched in 2018, is backed by Third Rock Ventures and GV (formerly Google Ventures), and is based in Cambridge, Mass. For more information, please visit http://www.celsiustx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190919005082/en/

Go here to read the rest:
Celsius Therapeutics Signs Multiple Agreements with Academic Institutions to Access Samples for the Identification of Novel Targets in Immune...

A compound may improve pancreatic cancer survival rate, scientists find – PhillyVoice.com

Scientists have discovered a compound could help slow down pancreatic cancer by targeting proteins that promote metastatic cells.

Researchers at Johns Hopkins Medicine found that the compound, 4-HAP, reduced tumors in mice and could improve survival for pancreatic cancer patients.

According to the National Cancer Institute, 73,554 people in the U.S. have pancreatic cancer and only 9.3 percent of those diagnosed survive five or more years.

The study, published in the journal Cancer Research, examined two types of proteins, mechanoresponsive proteins and non-mechanoresponsive proteins.

Scientists looked at a total of seven proteins, including nonmuscle myosin IIA, IIB and IIC; alpha-actinin 1 and 4; and filamin A and B. The mechanoresponsive proteins IIA, IIC, active actinin 4 and filamin B increased cancer tissue in the pancreas by over-producing the cancer cells.

Scientists found that even though the protein nonmuscle myosin IIC was found to be low in the cancer cells it had a profound impact on the cell's overall function. When they exposed these proteins to 4-HAP, it increased the cells' overall structure and stiffened the cells.

The group then tested 4-HAP as a treatment for pancreatic cancer by using a mouse model that had human pancreatic tissue implanted in the mouse's liver. They found that the tumors reduced by 50 percent.Researchers believe that treating the cells with the compound will allow scientists to target cancerous cells while protecting the healthy cells in the pancreas.

Follow Virginia & PhillyVoice on Twitter: @vastreva | @thePhillyVoiceLike us on Facebook: PhillyVoiceAdd Virginia's RSS feed to your feed readerHave a news tip? Let us know.

The rest is here:
A compound may improve pancreatic cancer survival rate, scientists find - PhillyVoice.com

Making Sense of Medicine: The meaning of life | Lifestyles – The Daily News of Newburyport

Ancient Greek philosopher Aristotle made what may be the first known attempt to define life. He said that something is alive if it grows, is animated and nourishes itself. A more recent definition suggests the important characteristics being the capacity for growth, reproduction, functional activity and continual change preceding death.

There are other attempts, but they all fail in some way. Both of these definitions, for example, would consider fire to be alive and mules, which are born sterile, not to be alive. All that said, most of us have an instinctive understanding of what it means to be alive. If you see a bug or a bird or even an amoeba, you are certain it possesses life.

None of this, however, tells us anything about how life first started or whence it came. Again, there are countless thoughts about this, such as life resulting from a stroke of lightning zapping just the right elements at the right time. Some believe radiation was the instigator, and some suggest that early life forms arrived on Earth aboard rocks from outer space. No one knows for sure.

However, there is research that shows the possibility of creating the basic building blocks of life, amino acids and proteins, from basic inorganic compounds by simulating the conditions that must have prevailed at Earths beginning. And research in cell biology has established some remarkably likely facts about how we became human.

Its all about cells?

A cell is the smallest functional unit of every living thing; we are made from trillions of them. The cell has a jelly-like liquid called cytoplasm enclosed in a membrane. Within the cytoplasm are structures with functions similar to our organs, and they are called organelles, or little organs, with names like mitochondria, lysosomes and others. With these, the cell can perform for itself all the same functions that we need for life: respiration, reproduction, waste removal, energy conversion and more.

Some cells have an organelle called the nucleus inside the membrane, as well. These are called eukaryotes, meaning to have a true (eu) nucleus (kary). A nucleus is important, as it contains most of the cells genes that are part of its DNA molecules; DNA is packaged in the form of chromosomes in order to fit into the nucleus. Other cells are called prokaryotes, meaning to exist before (pro) a nucleus occurs; bacteria are prokaryotes. They, too, have DNA, but its located directly in the cytoplasm.

The organelles are like computer programs, apps, in that they can perform specific functions, but they have to be started by a brain. The important fact is that cells are intelligent, and their brain is the cell membrane. The membrane includes tens of thousands of IMPs (integral membrane proteins) that receive and send signals from and to their environment, directing the organelles to do their thing and so create the complex behavior of a living cell.

A brief timeline

Earth was created about 41/2 billion years ago, but it wasnt until 3.8 billion years ago that single-cell prokaryotes appeared. That is, the bacteria have been here a seriously long time.

The eukaryotes evolved from prokaryotes, appearing about 21/2 billion years ago, and the kind of life forms we experience today are only about 600 million years old. There were no mammals until about 200 million years ago, and we, Homo sapiens, have been around for a mere 200,000 years. So, what happened to get from the first eukaryotes to us?

Community building

For the first 3 billion years that there was life on Earth, it consisted of independent single cells, monads. They were bacteria, they were algae, they were protozoans and some fungi. It was long thought that they were solitary.

Research has shown, however, that the signals they use to organize their own physiology can be released into their environment, creating a kind of long-distance communication. For example, amoebas consuming food release a particular molecule that informs other amoebas of a supply of food to which many are then drawn. Other signal molecules like hormones were in use by these single-cell critters, as well.

As time passed, monads learned to increase the number of IMPs in their membrane and started to assemble themselves into close-knit cellular communities for survival. As the size and complexity of these multicellular communities grew, they became highly organized and parceled out specific functions to specialized groups of cells: forming body tissues and organs, building nervous and immune systems, etc. And so there evolved the complex organisms we recognize as plants and animals.

As the more complex animals evolved, there were specialized cells that became responsible for monitoring and regulating the flow of signaling among other cells. This central information processor became the brain that controls the overall interaction and behavior of all the cells in the body. We commonly believe that our mind is the same as our brain and is located our head. However, neuroscientist and pharmacologist Candace Perts elegant experiments showed that the mind is distributed throughout the body.

We as humans, and, in fact, all mammals and some others, are an advanced stage of this kind of community organization. Of special interest is the development of a region of the brain called the prefrontal cortex. In this, we find the capacity for thinking, planning and decision-making, as well as the seat of self-consciousness.

And so ...

Cellular communities continue to evolve, giving new perspectives on what it means to be alive.

Bob Keller maintains a holistic practice in Newburyport. He offers medical massage therapy for pain relief, as well as psychological counseling, dream work and spiritual direction. Many patients call him Dr. Bob and accuse him of doing miracles, but he is not a medical doctor nor a divinity. His expertise is medical massage therapy, understanding this miracle we call the human being. He can be reached at 978-465-5111 or rk2name@gmail.com.

Link:
Making Sense of Medicine: The meaning of life | Lifestyles - The Daily News of Newburyport

#E#ECTRIMS2019 – In Progressive MS, ATA188 Showing Safety and Hints of Effectiveness in Phase 1 Trial – Multiple Sclerosis News Today

People with progressive forms of multiple sclerosis (MS) and past exposure to the Epstein-Barr virus are responding to a potentialimmunotherapy known as ATA188, tolerating the treatment well and with signs that suggest effectiveness, early updated data from an ongoing Phase 1 trial show.

The research, Preliminary safety and efficacy of ATA188, a pre-manufactured, unrelated donor (off-the-shelf, allogeneic) Epstein-Barr virus-targeted T-cell immunotherapy for patients with progressive forms of multiple sclerosis, was presented at the 35thCongress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)held in Stockholm (Sept. 1113).

Infection with the Epstein-Barr virus (EBV)is linked to a greater susceptibility to MS. EBV promotes the expansion of immune B-cells, which can produce autoantibodies against myelin, the protective coating of nerve fibers that is progressively damaged in this disease.

People with MS are believed to be deficient in T-cells, which would normally kill EBV-infected B-cells.

ATA188, byAtara Biotherapeutics, is designed to overcome this deficiency by providing allogeneic immune T-cells that target EBV in B-cells. (Allogeneic cells are from donors with no family or genetic relationship to the recipient; an advantage is that these cells are available immediately, or off-the-shelf.)

The Phase 1 study (NCT03283826), taking place in the U.S. and Australia, is assessing the safety and efficacy of ATA188 in progressive MS patents here, a near equal mix of secondary progressive disease (SPMS) and primary progressive MS (PPMS) ages 18 to 66. Patients are assigned to four groups, each testing a different cell dose: 5 x 106, 1 x 107, 2 x 107, and 4 x 107.

Clinically recognized MS scales are assessing ATA188 effectiveness at baseline (study start), and at roughly 3, 6, and 12 months after initial treatment. These include the Expanded Disability Status Scale(EDSS), the Fatigue Severity Score, the MS Impact Scale, the Timed 25-Foot Walk (T25FW) where patients walk 25 feet as quickly and safely as possible the 9-Hole Peg Test of hand and finger skills, 12-Item MS Walking Scale, and tests of visual acuity.

Early data previously reportedshowed that treatment with ATA188 was well-tolerated across the four groups, with no evidence of cytokine release syndrome(a form of systemic inflammatory response), graft versus host disease(which refers to the attack of the hosts cells by transplanted stem cells), or dose-limiting toxicities.

Preliminary data now reported at ECTRIMS, collected through July 29, 2019, covered the four groups of six patients each (median age, 56).

Results found no dose-limiting toxicities. There were also no reports ofclinically significant laboratory abnormalities in any of the groups.

One patient in group 4 (using 4 x 107cells) dropped out of the study due to aMS relapse that took place in the setting of an ongoing URI [upper respiratory tract infection] and possible dental infection, the researchers reported at ECTRIMS.

Safety results showed that across the four planned dose cohorts, ATA188 was well tolerated in patients with progressive forms of MS, with no evidence of cytokine release syndrome, graft versus host disease, or dose-limiting toxicities, they added.

Efficacy data were available from the first two groups, and hints of benefit were seen.

Four of the six patients in group 1 the lowest dose group showed clinical decline at 6 and 12 months, defined as worsening in two or moreMS scales compared to baseline. The other two showed at least partial improvement in these scales at month six, with one of these showing stable disease at 12 months.

In group 2 (1 x 107),all six patients showed either clinical improvement (two people) or partial clinical improvement (four people) at six months, or improvements in two or more or more MS scales. Data for this group did not stretch out 12 months.

Better results in terms of lesser disability were seen in people in group 2, where only one person experienced clinical decline compared to four of the six patients in group 1.

These preliminary results support continuing the trial to identify the dose for both the OLE [open-label extension] and the randomized, double-blind, placebo-controlled portion (part 2) of the study, the researchers wrote.

I am encouraged by the well tolerated safety profile, as well as early findings of potential efficacy in the ongoing ATA188 Phase 1 study, Amit Bar-Or, MD, a principal investigator in the trial and chief of MS Divisionat thePerelman School of Medicine at the University of Pennsylvania, said in apress release.

He also favored this studys innovative approach, that of using multiple MS scales to measure benefit.

I look forward to advancing the study alongside my colleagues for progressive MS patients who have limited treatment options,and where continual clinical decline is expected, Bar-Or added.

These early data support the potential of a T-cell immunotherapy targeting EBV-infected B-cells in progressive MS, said AJ Joshi, MD, Ataras senior vice president and chief medical officer.

Our recent completion of enrollment in the fourth and final dose escalation cohort moves us closer to identifying the dose to be used in the studys placebo-controlled Phase 1b part, Joshi added.We are committed to advancing ATA188 for MS patients, and look forward to presenting additional efficacy and safety results from this study in 2020, including from cohorts 3 and 4.

Of note, eight of the studys 14 authors are employees and stockholders of Atara. One other is a member of the companys Neurology Clinical Advisory Panel.

Jos is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has studied Biochemistry also at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario, in London, Ontario. His work ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimers disease.

Total Posts: 1,053

Patrcia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

More here:
#E#ECTRIMS2019 - In Progressive MS, ATA188 Showing Safety and Hints of Effectiveness in Phase 1 Trial - Multiple Sclerosis News Today